Key result
Abstract lacks clinical data on the long-term benefits of pulsed field ablation.
No results in abstract to guide pulsed field ablation use; leaves open long-term benefit assessment.
The authors thank all inspIRE study (Study for Treatment of Paroxysmal Atrial Fibrillation [PAF] by Pulsed Field Ablation [PFA] System With Irreversible Electroporation [IRE]) personnel and patients for their valuable participation in this trial. The authors thank the following individuals for their efforts in trial execution, statistical analysis, and input during the development of this article: Christina Kaneko, Jaclyn Alcazar, Guixia Huang, Stephen Hynes, Ramona Wu, Carmen Rousseeuw, Sarah Rabau, and Nathalie Marcours. Michelle Hughes, PhD, of Lumanity Communications Inc, provided medical writing and editorial support, funded by Biosense Webster, Inc, under the direction of the authors. The inspIRE Trial Investigators: Luigi Di Biase, Jim Hansen, Sebastien Knecht, Georgios Kollias, Peter Lukac, Andrea Natale, Jan Petru, and Thomas Phlips.
No takes yet. Share an insight, caveat, or question.
Potter et al. (2025) studied Paroxysmal Atrial Fibrillation. Pulsed Field Ablation (PFA) System With Irreversible Electroporation (IRE) was evaluated. The provided abstract contains only acknowledgments and provides no clinical data or results regarding the long-term clinical benefits of pulsed field ablation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: